Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ADR009
MIFTS: 38

Adrenal Cortex Disease

Categories: Endocrine diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Adrenal Cortex Disease

About this section

MalaCards integrated aliases for Adrenal Cortex Disease:

Name: Adrenal Cortex Disease 12 15
Adrenal Cortex Diseases 44 73

Classifications:

MalaCards categories:
Anatomical: Endocrine diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:3952
MeSH 44 D000303
UMLS 73 C0001614
Sources

Summaries for Adrenal Cortex Disease

About this section
MalaCards based summary : Adrenal Cortex Disease, also known as adrenal cortex diseases, is related to primary pigmented nodular adrenocortical disease and acute adrenal insufficiency. An important gene associated with Adrenal Cortex Disease is POMC (Proopiomelanocortin), and among its related pathways/superpathways are Aldosterone synthesis and secretion and G alpha (s) signalling events. The drugs Mecasermin and Mitotane have been mentioned in the context of this disorder. Affiliated tissues include cortex, adrenal cortex and adrenal gland, and related phenotypes are Reduced mammosphere formation and behavior/neurological

Wikipedia : 76 Situated along the perimeter of the adrenal gland, the adrenal cortex mediates the stress response... more...

Sources

Related Diseases for Adrenal Cortex Disease

About this section

Diseases related to Adrenal Cortex Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 92)
# Related Disease Score Top Affiliating Genes
1 primary pigmented nodular adrenocortical disease 31.6 NR3C1 PDE11A POMC PRKAR1A
2 acute adrenal insufficiency 10.3 POMC REN
3 ovarian serous adenofibroma 10.3 NR3C1 POMC
4 gangliocytoma 10.3 CRH POMC
5 inappropriate adh syndrome 10.2 POMC REN
6 allergic urticaria 10.2 CRH NR3C1
7 hypoaldosteronism 10.2 CYP11B2 POMC REN
8 bronchus adenoma 10.2 POMC SST
9 bronchial adenomas/carcinoids childhood 10.2 POMC SST
10 acidophil adenoma 10.2 POMC SST
11 aldosterone-producing adenoma 10.2 CYP11B2 KCNJ5
12 acth deficiency, isolated 10.2 CRH POMC
13 arthrogryposis, distal, type 3 10.2 NR3C2 REN
14 mental depression 10.2 CRH NR3C1 POMC
15 persistent fetal circulation syndrome 10.2 CRH HSD11B2 POMC
16 postural hypotension 10.2 REN SST
17 chronic fatigue syndrome 10.2 CRH NR3C1 POMC
18 corticosteroid-binding globulin deficiency 10.2 HSD11B2 NR3C1 POMC
19 pseudohypoaldosteronism, type i, autosomal dominant 10.2 NR3C2 REN
20 adenohypophysitis 10.2 POMC PRL
21 familial hyperaldosteronism 10.2 CYP11B1 CYP11B2 KCNJ5
22 ectopic cushing syndrome 10.2 CRH POMC SST
23 mood disorder 10.1 CRH NR3C1 POMC
24 hormone producing pituitary cancer 10.1 PRKAR1A SST
25 pseudohyperkalemia, familial, 2, due to red cell leak 10.1 CYP11B2 NR3C2 REN
26 pancreatic endocrine carcinoma 10.1 POMC SST
27 anuria 10.1 HSD11B2 NR3C2 REN
28 glucose metabolism disease 10.1 POMC REN SST
29 pituitary apoplexy 10.1 POMC PRL
30 hypothalamic disease 10.1 CRH POMC PRL
31 male reproductive organ benign neoplasm 10.1 POMC PRKAR1A
32 sheehan syndrome 10.1 CRH POMC PRL
33 hypothyroidism, congenital, nongoitrous, 4 10.1 CRH POMC PRL
34 hypoadrenalism 10.1 CRH POMC
35 sella turcica neoplasm 10.1 POMC PRL
36 amenorrhea 10.1 CRH POMC PRL
37 hypopituitarism 10.1 CRH POMC PRL
38 tuberculum sellae meningioma 10.1 POMC PRL
39 adrenal carcinoma 10.1 CRH CYP11B1 CYP11B2 POMC REN
40 melancholia 10.1 CRH PRL
41 familial hypertension 10.1 CYP11B2 HSD11B2 NR3C2 REN
42 pituitary infarct 10.0 POMC PRL SST
43 anorexia nervosa 10.0 CRH POMC PRL
44 chiasmal syndrome 10.0 POMC PRL SST
45 empty sella syndrome 10.0 POMC PRL
46 premenstrual tension 10.0 CRH POMC PRL REN
47 hyperpituitarism 10.0 POMC PRL SST
48 glucocorticoid deficiency 1 10.0 MC2R POMC
49 prolactin producing pituitary tumor 10.0 PRL SST
50 tsh producing pituitary tumor 10.0 POMC PRL SST

Graphical network of the top 20 diseases related to Adrenal Cortex Disease:



Diseases related to Adrenal Cortex Disease
Sources

Symptoms & Phenotypes for Adrenal Cortex Disease

About this section

GenomeRNAi Phenotypes related to Adrenal Cortex Disease according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.23 CYP11B1 HSD11B2 KCNJ5 MC2R NR0B1 NR3C1

MGI Mouse Phenotypes related to Adrenal Cortex Disease:

46 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.31 AIRE CRH CYP11B1 HSD11B2 MC2R NR3C1
2 homeostasis/metabolism MP:0005376 10.31 AIRE ARMC5 CRH CYP11B1 CYP11B2 HSD11B2
3 growth/size/body region MP:0005378 10.25 AIRE ARMC5 CRH CYP11B1 CYP11B2 MC2R
4 cardiovascular system MP:0005385 10.22 CYP11B1 CYP11B2 HSD11B2 KCNJ5 MC2R NR3C1
5 endocrine/exocrine gland MP:0005379 10.2 AIRE ARMC5 CRH CYP11B1 CYP11B2 MC2R
6 immune system MP:0005387 10.07 AIRE CRH CYP11B2 MC2R NR3C1 POMC
7 mortality/aging MP:0010768 10.03 AIRE ARMC5 CYP11B1 HSD11B2 MC2R NR3C1
8 adipose tissue MP:0005375 9.99 CRH CYP11B2 MC2R NR3C1 POMC PRKAR1A
9 liver/biliary system MP:0005370 9.92 AIRE CRH CYP11B2 NR3C1 POMC PRKAR1A
10 nervous system MP:0003631 9.7 AIRE CRH CYP11B2 MC2R NR3C1 NR3C2
11 neoplasm MP:0002006 9.63 AIRE HSD11B2 NR0B1 POMC PRKAR1A PRL
12 renal/urinary system MP:0005367 9.23 CRH CYP11B1 CYP11B2 HSD11B2 NR3C1 NR3C2
Sources

Drugs & Therapeutics for Adrenal Cortex Disease

About this section

Drugs for Adrenal Cortex Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 169)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mecasermin Approved, Investigational Phase 3 68562-41-4
2
Mitotane Approved Phase 3,Phase 2 53-19-0 4211
3
Lenograstim Approved, Investigational Phase 3 135968-09-1
4
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
5
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
6
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
7
Streptozocin Approved, Investigational Phase 3 18883-66-4 29327
8
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
9 Antineoplastic Agents, Hormonal Phase 3,Phase 2
10 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
11 Antimitotic Agents Phase 3,Phase 2,Phase 1
12 Insulin, Globin Zinc Phase 3,Phase 2
13 insulin Phase 3,Phase 2
14 Mitogens Phase 3,Phase 2
15 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
16 Immunologic Factors Phase 3,Phase 2,Phase 1
17 Adjuvants, Immunologic Phase 3,Phase 2,Phase 1
18 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable
19 Etoposide phosphate Phase 3,Phase 2
20 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
21 Keratolytic Agents Phase 3
22 Podophyllotoxin Phase 3 518-28-5
23 Dermatologic Agents Phase 3
24
Nicotinamide Approved, Investigational Phase 2 98-92-0 936
25
Paclitaxel Approved, Vet_approved Phase 2,Phase 1 33069-62-4 36314
26
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
27
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
28
Racepinephrine Approved Phase 2,Phase 1,Not Applicable 329-65-7 838
29
Epinephrine Approved, Vet_approved Phase 2,Phase 1,Not Applicable 51-43-4 5816
30
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2,Phase 1 1177-87-3
31
Dexamethasone Approved, Investigational, Vet_approved Phase 2,Phase 1 50-02-2 5743
32
Hydrocortisone acetate Approved, Vet_approved Phase 2,Phase 1,Not Applicable 50-03-3
33
Hydrocortisone Approved, Vet_approved Phase 2,Phase 1,Not Applicable 50-23-7 5754
34
Axitinib Approved, Investigational Phase 2 319460-85-0 6450551
35
acetic acid Approved Phase 2 64-19-7 176
36
Etomidate Approved Phase 1, Phase 2 33125-97-2 667484 36339
37
Vincristine Approved, Investigational Phase 2 57-22-7, 2068-78-2 5978
38
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
39
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
40
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 43805 6857599 5310940 9887054
41
Tamoxifen Approved Phase 2 10540-29-1 2733526
42
Nivolumab Approved Phase 2,Phase 1 946414-94-4
43
Pembrolizumab Approved Phase 2 1374853-91-4
44
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
45
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
46
Vitamin A Approved, Nutraceutical, Vet_approved Phase 2 11103-57-4, 68-26-8 445354
47
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
48
Lactitol Investigational Phase 2 585-86-4 3871
49 Gossypol Investigational Phase 2 303-45-7
50
Suramin Investigational Phase 2,Phase 1 145-63-1 5361

Interventional clinical trials:

(show top 50) (show all 78)
# Name Status NCT ID Phase Drugs
1 A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma Completed NCT00924989 Phase 3 OSI-906
2 Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor Completed NCT00304070 Phase 3 doxorubicin hydrochloride;cisplatin;mitotane;etoposide
3 Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT) Completed NCT00094497 Phase 3 Etoposide;Doxorubicin;Cisplatin;Streptozotocin;Mitotane
4 Adjuvant Chemotherapy vs. Observation/Mitotane After Primary Surgical Resection of Localized Adrenocortical CarcInoma Recruiting NCT03723941 Phase 3 Cisplatin plus Etoposide
5 Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Participants With Stage I-III Adrenocortical Cancer With High Risk of Recurrence (ADIUVO-2) Recruiting NCT03583710 Phase 3 Cisplatin;Etoposide;Mitotane
6 Efficacy of Adjuvant Mitotane Treatment (ADIUVO) Recruiting NCT00777244 Phase 3 MITOTANE
7 Sorafenib Plus Paclitaxel in Adreno-Cortical-Cancer Patients Unknown status NCT00786110 Phase 2 Sorafenib;Paclitaxel
8 Sunitinib in Refractory Adrenocortical Carcinoma Unknown status NCT00453895 Phase 2 Sunitinib
9 Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome Completed NCT02468193 Phase 2 Osilodrostat
10 Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492 Completed NCT02150213 Phase 2 BGG492
11 Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-Pathway in Metastatic, Recurrent or Primary Unresectable Adrenocortical Cancer Completed NCT01255137 Phase 2 Axitinib
12 Surgery and Heated Chemotherapy for Adrenocortical Carcinoma Completed NCT01833832 Phase 2 Cisplatin;sodium thiosulfate
13 Clinical Trial of Dovitinib in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical Carcinoma Completed NCT01514526 Phase 2 Dovitinib
14 A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients Completed NCT01262235 Phase 1, Phase 2 TKM-080301
15 Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery Completed NCT00848016 Phase 2 R-(-)-gossypol acetic acid
16 Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors Completed NCT00831844 Phase 2
17 Evaluation of 123I-Iodometomidate for Adrenal Scintigraphy Completed NCT00454103 Phase 1, Phase 2 123I-Iodometomidate
18 Surgery Plus Chemotherapy (Doxorubicin, Vincristine and Etoposide), Mitotane, and Tariquidar to Treat Adrenocortical Cancer Completed NCT00071058 Phase 2 XR9576 (Tariquidar)
19 Trial With Taxotere and Cisplatin in Non-operable Adrenocortical Carcinoma Completed NCT00324012 Phase 2 cisplatin, taxotere
20 Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC) Completed NCT00215202 Phase 2 Iressa (ZD1839)
21 Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment Completed NCT00091182 Phase 2 oxaliplatin
22 Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
23 A Study of Combination Chemotherapy and Surgical Resection in the Treatment of Adrenocortical Carcinoma: Continuous Infusion Doxorubicin, Vincristine and Etoposide With Daily Mitotane Before and After Surgical Resection Completed NCT00001339 Phase 2 doxorubicin, vincristine, and etoposide with mitotane
24 Cabozantinib in Unresectable/Metastatic Adrenocortical Carcinoma Recruiting NCT03370718 Phase 2 Cabozantinib
25 Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors Recruiting NCT03333616 Phase 2 Ipilimumab;Nivolumab
26 Cabazitaxel Activity in Patients With Advanced AdrenoCortical-Carcinoma Progressing After Previous Chemotherapy Lines Recruiting NCT03257891 Phase 2 Cabazitaxel
27 Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma Recruiting NCT03127774 Phase 2 Cisplatin;Sodium thiosulfate
28 Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Recruiting NCT02867592 Phase 2 Cabozantinib S-malate
29 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
30 Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic Recruiting NCT02721732 Phase 2
31 Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma Recruiting NCT02673333 Phase 2 Pembrolizumab
32 Activity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical Carcinoma Active, not recruiting NCT03145285 Phase 2 Abiraterone Acetate
33 Nivolumab in Treating Patients With Metastatic Adrenocortical Cancer Active, not recruiting NCT02720484 Phase 2 Nivolumab
34 Cabozantinib in Advanced Adrenocortical Carcinoma Not yet recruiting NCT03612232 Phase 2 Cabozantinib-s-malate
35 IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That Cannot Be Removed by Surgery Terminated NCT00778817 Phase 2 mitotane
36 S9427, Suramin in Treating Patients With Stage III or Stage IV Adrenocortical Cancer Incurable by Surgery Terminated NCT00002921 Phase 2 suramin;therapeutic hydrocortisone
37 Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland Cancer Terminated NCT00003453 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
38 Treatment Study Using Bevacizumab for Patients With Adrenocortical Carcinoma Withdrawn NCT00469469 Phase 2 Bevacizumab
39 Adrenal Responsiveness During the Perioperative Period in Children Undergoing Congenital Cardiac Surgery Completed NCT01839812 Phase 1 Cosyntropin
40 Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma Completed NCT01898715 Phase 1 ATR-101
41 Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features Completed NCT01048892 Phase 1 cyclophosphamide
42 Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin for Children With Peritoneal Cancer Completed NCT00436657 Phase 1 CHPP of Cisplatin
43 Combination Chemotherapy With Suramin Plus Doxorubicin in Treating Patients With Advanced Solid Tumors Completed NCT00003038 Phase 1 doxorubicin hydrochloride;suramin
44 Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Completed NCT00004074 Phase 1
45 A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 Recruiting NCT02637531 Phase 1 IPI-549;Nivolumab
46 Possible New Therapy for Advanced Cancer Terminated NCT01832974 Phase 1 IL-13-PE
47 Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor Withdrawn NCT02831179 Phase 1 Capecitabine;Temozolomide;Veliparib
48 The Effects of Case Management in a Medicaid Managed Care Plan Unknown status NCT00385879 Not Applicable
49 Does Serum-DXM Increase Diagnostic Accuracy of the Overnight DXM Suppression Test in the Work-up of Cushing's Syndrome? Unknown status NCT01504555
50 Long-term Beneficial Metabolic Effects of Adrenalectomy in Subclinical Cushing's Syndrome of Adrenal Incidentaloma Unknown status NCT01382420 Not Applicable

Search NIH Clinical Center for Adrenal Cortex Disease

Cochrane evidence based reviews: adrenal cortex diseases

Sources

Genetic Tests for Adrenal Cortex Disease

About this section
Sources

Anatomical Context for Adrenal Cortex Disease

About this section

MalaCards organs/tissues related to Adrenal Cortex Disease:

41
Cortex, Adrenal Cortex, Adrenal Gland, Pituitary, Thyroid
Sources

Publications for Adrenal Cortex Disease

About this section

Articles related to Adrenal Cortex Disease:

# Title Authors Year
1
Hypertension and adrenal cortex disease. A review of 100 autopsied cases. ( 5491407 )
1970
Sources

Variations for Adrenal Cortex Disease

About this section
Sources

Expression for Adrenal Cortex Disease

About this section
Search GEO for disease gene expression data for Adrenal Cortex Disease.
Sources

Pathways for Adrenal Cortex Disease

About this section

Pathways related to Adrenal Cortex Disease according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1
Aldosterone synthesis and secretion 37
Show member pathways
 12.31 CYP11B1 CYP11B2 KCNJ5 MC2R NR0B1 POMC
2
G alpha (s) signalling events 66
11.72 CRH MC2R PDE11A POMC
3
Corticotropin-releasing hormone signaling pathway 1
11.62 CRH CYP11B1 POMC
4
Nuclear Receptor transcription pathway 66
Show member pathways
 11.59 NR0B1 NR3C1 NR3C2
5
Cushing syndrome 37
Show member pathways
 11.57 ARMC5 CRH CYP11B1 MC2R PDE11A POMC
6
Glucocorticoid receptor regulatory network 1
11.52 NR3C1 POMC PRL
7
Agents Acting on the Renin-Angiotensin System Pathway, Pharmacodynamics 61
Show member pathways
 11.48 CYP11B2 NR3C2 REN
8
Steroid hormone biosynthesis 37
Show member pathways
 11.36 CYP11B1 CYP11B2 HSD11B2
9
Metabolism of steroid hormones 66
Show member pathways
 11.2 CYP11B1 CYP11B2 HSD11B2 POMC
10
superpathway of steroid hormone biosynthesis 1
Show member pathways
 10.82 CYP11B1 CYP11B2
11
Glucocorticoid Pathway (HPA Axis), Pharmacodynamics 61
10.17 CRH POMC
Sources

GO Terms for Adrenal Cortex Disease

About this section

Cellular components related to Adrenal Cortex Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.44 AIRE ARMC5 CRH HSD11B2 MC2R NR0B1

Biological processes related to Adrenal Cortex Disease according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.8 CRH HSD11B2 PRL REN SST
2 steroid metabolic process GO:0008202 9.74 CRH CYP11B1 CYP11B2
3 female pregnancy GO:0007565 9.73 CRH HSD11B2 PRL
4 regulation of blood pressure GO:0008217 9.67 CYP11B1 POMC REN
5 steroid biosynthetic process GO:0006694 9.65 CYP11B1 CYP11B2 NR0B1
6 cellular response to hormone stimulus GO:0032870 9.61 CYP11B1 CYP11B2 PRL
7 adrenal gland development GO:0030325 9.58 CRH NR0B1
8 cellular response to peptide hormone stimulus GO:0071375 9.58 CYP11B1 CYP11B2
9 hypothalamus development GO:0021854 9.55 CRH NR0B1
10 C21-steroid hormone biosynthetic process GO:0006700 9.54 CYP11B1 CYP11B2
11 parturition GO:0007567 9.52 CRH PRL
12 cellular response to potassium ion GO:0035865 9.51 CYP11B1 CYP11B2
13 hormone-mediated apoptotic signaling pathway GO:0008628 9.46 CRH SST
14 cellular response to dexamethasone stimulus GO:0071549 9.43 CRH NR3C1 USP8
15 aldosterone biosynthetic process GO:0032342 9.37 CYP11B1 CYP11B2
16 cortisol biosynthetic process GO:0034651 9.32 CYP11B1 CYP11B2
17 regulation of blood volume by renal aldosterone GO:0002017 9.16 CYP11B2 HSD11B2
18 response to immobilization stress GO:0035902 9.13 CRH NR0B1 REN
19 glucocorticoid biosynthetic process GO:0006704 8.92 CRH CYP11B1 CYP11B2 HSD11B2

Molecular functions related to Adrenal Cortex Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 steroid hormone receptor activity GO:0003707 9.5 NR0B1 NR3C1 NR3C2
2 steroid binding GO:0005496 9.43 HSD11B2 NR3C1 NR3C2
3 3',5'-cyclic-GMP phosphodiesterase activity GO:0047555 9.37 PDE11A PRKAR1A
4 corticosterone 18-monooxygenase activity GO:0047783 9.16 CYP11B1 CYP11B2
5 steroid 11-beta-monooxygenase activity GO:0004507 8.96 CYP11B1 CYP11B2
6 hormone activity GO:0005179 8.92 CRH POMC PRL SST
Sources

Sources for Adrenal Cortex Disease

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....